Breast Cancer and Tamoxifen: A Nigerian Perspective to Effective Personalised Therapy

Ayorinde Adehin,1,2 Martin Alexander Kennedy,3 Julius Olugbenga Soyinka,1 Olusegun Isaac Alatise,4 Olalekan Olasehinde,4 Oluseye Oladotun Bolaji1 1Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Obafemi Awolowo University, Ile-Ife, Nigeria; 2Institute of Biomedical and Pharmaceutical Sc...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Adehin A, Kennedy MA, Soyinka JO, Alatise OI, Olasehinde O, Bolaji OO
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2020
Materias:	breast cancer estrogen receptor tamoxifen nigeria epigenetics genomics Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/de3ee25b2dc741d083b7773d4bf14d99
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:de3ee25b2dc741d083b7773d4bf14d99
record_format	dspace
spelling	oai:doaj.org-article:de3ee25b2dc741d083b7773d4bf14d992021-12-02T10:18:25ZBreast Cancer and Tamoxifen: A Nigerian Perspective to Effective Personalised Therapy1179-1314https://doaj.org/article/de3ee25b2dc741d083b7773d4bf14d992020-10-01T00:00:00Zhttps://www.dovepress.com/breast-cancer-and-tamoxifen-a-nigerian-perspective-to-effective-person-peer-reviewed-article-BCTThttps://doaj.org/toc/1179-1314Ayorinde Adehin,1,2 Martin Alexander Kennedy,3 Julius Olugbenga Soyinka,1 Olusegun Isaac Alatise,4 Olalekan Olasehinde,4 Oluseye Oladotun Bolaji1 1Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Obafemi Awolowo University, Ile-Ife, Nigeria; 2Institute of Biomedical and Pharmaceutical Sciences, Guangdong University of Technology, Guangzhou, People’s Republic of China; 3Department of Pathology and Biomedical Science; Carney Centre of Pharmacogenomics, University of Otago, Christchurch, New Zealand; 4Department of Surgery, Faculty of Clinical Sciences, College of Health Sciences, Obafemi Awolowo University, Ile-Ife, NigeriaCorrespondence: Ayorinde Adehin Department of Pharmaceutical Chemistry, Faculty of PharmacyObafemi Awolowo University, Ile-Ife, NigeriaTel +234 8022013470Email aadehin@oauife.edu.ngAbstract: Estrogen-receptor positivity in tumour, often requiring long-term tamoxifen therapy, is thought to characterise between 43% and 65% of breast cancer cases in Nigeria. The patient population is further marked by late-stage diagnosis which significantly heightens the tendency for tumour relapse in the course of tamoxifen therapy. Despite tamoxifen being considered a reliable chemopreventive in high-risk individuals and an effective adjuvant therapy for hormone-sensitive tumours, mortality has remained high among breast cancer patients in the West African region where Nigeria belongs. The Nigerian breast cancer population, like other similar patient-populations in the West African region, provides a mix of intrinsic genome-diversity and perhaps unique tumour biology and evolution. These peculiarities suggest the need for a rational approach to tumour management and a personalised delivery of therapy in Nigeria’s dominant estrogen-receptor-positive patient population. Herein, critical indices of tamoxifen-therapy success are discussed in the context of the Nigerian breast cancer population with emphasis on salient aspects of tamoxifen-biotransformation, host- and tumour-genomics, and epigenetics.Keywords: breast cancer, estrogen receptor, tamoxifen, Nigeria, epigenetics, genomicsAdehin AKennedy MASoyinka JOAlatise OIOlasehinde OBolaji OODove Medical Pressarticlebreast cancerestrogen receptortamoxifennigeriaepigeneticsgenomicsNeoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282ENBreast Cancer: Targets and Therapy, Vol Volume 12, Pp 123-130 (2020)
institution	DOAJ
collection	DOAJ
language	EN
topic	breast cancer estrogen receptor tamoxifen nigeria epigenetics genomics Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
spellingShingle	breast cancer estrogen receptor tamoxifen nigeria epigenetics genomics Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 Adehin A Kennedy MA Soyinka JO Alatise OI Olasehinde O Bolaji OO Breast Cancer and Tamoxifen: A Nigerian Perspective to Effective Personalised Therapy
description	Ayorinde Adehin,1,2 Martin Alexander Kennedy,3 Julius Olugbenga Soyinka,1 Olusegun Isaac Alatise,4 Olalekan Olasehinde,4 Oluseye Oladotun Bolaji1 1Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Obafemi Awolowo University, Ile-Ife, Nigeria; 2Institute of Biomedical and Pharmaceutical Sciences, Guangdong University of Technology, Guangzhou, People’s Republic of China; 3Department of Pathology and Biomedical Science; Carney Centre of Pharmacogenomics, University of Otago, Christchurch, New Zealand; 4Department of Surgery, Faculty of Clinical Sciences, College of Health Sciences, Obafemi Awolowo University, Ile-Ife, NigeriaCorrespondence: Ayorinde Adehin Department of Pharmaceutical Chemistry, Faculty of PharmacyObafemi Awolowo University, Ile-Ife, NigeriaTel +234 8022013470Email aadehin@oauife.edu.ngAbstract: Estrogen-receptor positivity in tumour, often requiring long-term tamoxifen therapy, is thought to characterise between 43% and 65% of breast cancer cases in Nigeria. The patient population is further marked by late-stage diagnosis which significantly heightens the tendency for tumour relapse in the course of tamoxifen therapy. Despite tamoxifen being considered a reliable chemopreventive in high-risk individuals and an effective adjuvant therapy for hormone-sensitive tumours, mortality has remained high among breast cancer patients in the West African region where Nigeria belongs. The Nigerian breast cancer population, like other similar patient-populations in the West African region, provides a mix of intrinsic genome-diversity and perhaps unique tumour biology and evolution. These peculiarities suggest the need for a rational approach to tumour management and a personalised delivery of therapy in Nigeria’s dominant estrogen-receptor-positive patient population. Herein, critical indices of tamoxifen-therapy success are discussed in the context of the Nigerian breast cancer population with emphasis on salient aspects of tamoxifen-biotransformation, host- and tumour-genomics, and epigenetics.Keywords: breast cancer, estrogen receptor, tamoxifen, Nigeria, epigenetics, genomics
format	article
author	Adehin A Kennedy MA Soyinka JO Alatise OI Olasehinde O Bolaji OO
author_facet	Adehin A Kennedy MA Soyinka JO Alatise OI Olasehinde O Bolaji OO
author_sort	Adehin A
title	Breast Cancer and Tamoxifen: A Nigerian Perspective to Effective Personalised Therapy
title_short	Breast Cancer and Tamoxifen: A Nigerian Perspective to Effective Personalised Therapy
title_full	Breast Cancer and Tamoxifen: A Nigerian Perspective to Effective Personalised Therapy
title_fullStr	Breast Cancer and Tamoxifen: A Nigerian Perspective to Effective Personalised Therapy
title_full_unstemmed	Breast Cancer and Tamoxifen: A Nigerian Perspective to Effective Personalised Therapy
title_sort	breast cancer and tamoxifen: a nigerian perspective to effective personalised therapy
publisher	Dove Medical Press
publishDate	2020
url	https://doaj.org/article/de3ee25b2dc741d083b7773d4bf14d99
work_keys_str_mv	AT adehina breastcancerandtamoxifenanigerianperspectivetoeffectivepersonalisedtherapy AT kennedyma breastcancerandtamoxifenanigerianperspectivetoeffectivepersonalisedtherapy AT soyinkajo breastcancerandtamoxifenanigerianperspectivetoeffectivepersonalisedtherapy AT alatiseoi breastcancerandtamoxifenanigerianperspectivetoeffectivepersonalisedtherapy AT olasehindeo breastcancerandtamoxifenanigerianperspectivetoeffectivepersonalisedtherapy AT bolajioo breastcancerandtamoxifenanigerianperspectivetoeffectivepersonalisedtherapy
_version_	1718397442249981952

Breast Cancer and Tamoxifen: A Nigerian Perspective to Effective Personalised Therapy

Ejemplares similares